Global stocks started the week quietly, with European and US stocks dropping on Monday, though the FTSE 100 approached last week’s record highs. AstraZeneca’s stock rose due to successful trials of its hypertension drug, Baxdrostat, which could potentially lead to annual sales of $5 billion. In the US, cryptocurrency stocks surged as Bitcoin hit a record high above $121,000. Coinbase’s stock climbed nearly 2%. This crypto rally is linked to possible legislative changes, such as the Clarity Act, which could boost Bitcoin’s use.

US Earnings Season Begins

This week kicks off the earnings season for US companies. Major banks like JP Morgan, Goldman Sachs, and tech leader Netflix will report results. Analysts are cautious, pointing to a weakening economy, as earnings estimates have been lowered across most sectors, except for communications. Despite these concerns, 59 out of 110 S&P 500 companies gave positive earnings guidance, especially in the tech sector. This suggests a level of optimism for the earnings season, particularly in technology and healthcare. Banking sector earnings will be closely watched, especially given recent trends and market volatility. Analysts will focus on loan loss provisions to gauge the economic outlook, with JP Morgan expected to benefit from higher US interest rates. With a slow start to trading this week and most markets pulling back—except for the UK’s main index—it feels more like a moment of pause than a shift in sentiment. The FTSE 100 showed resilience, hovering near previous highs, partly due to AstraZeneca’s strong performance. Investors reacted positively to clear clinical data and projected revenue from Baxdrostat. When a long-term treatment shows promise and estimates suggest significant revenue, traders take notice. In the US, the crypto surge is hard to ignore. Coinbase’s rise followed Bitcoin testing new records around $121,000. This increase isn’t just based on technical factors; it’s driven by policy changes. The proposed Clarity Act could redefine how digital currencies are utilized, enhancing their everyday applications. While it isn’t law yet, the market perceives it as likely.

Banking Sector’s Role in Earnings Season

The start of the earnings season often compels traders to reassess risk or quickly adjust their positions. The banks will lead this time, with JP Morgan and Goldman Sachs set to announce earnings. With the economic landscape appearing shaky, especially due to declining demand and tightening credit, a cautious outlook is prudent. Analysts have already lowered expectations across nearly all sectors. Despite these downgrades, the overall sentiment tells a different story. More than half of the S&P 500 firms providing guidance have maintained a positive outlook, particularly in tech. This shift from caution to hope is where recent market flows are heading. Positive forecasts may be concentrated but are not isolated. For those monitoring banking reports, a few key factors will shape the narrative. Loan loss provisions will be scrutinized; any rise in these could signal credit stress. However, JP Morgan is in a unique position, likely benefiting from higher federal interest rates, which enhance net interest margins even as lending slows. This highlights that while rate hikes can be tough for borrowers, they can also bolster bank balance sheets if managed well. As traders, it’s essential to stay adaptable. Macro data will influence risk sentiment, but in the short term, earnings—with their surprises and revised forecasts—will drive market movements. Monitoring sector performance, tracking capital shifts from defensive to growth stocks, and remaining agile with popular names can help navigate market fluctuations. Create your live VT Markets account and start trading now.

here to set up a live account on VT Markets now